Several small molecule inhibitors targeting PAK4, such as ATP-competitive inhibitors like PF-3758309 and LCH-7749944, have shown promising effects in different cancers in preclinical models by inhibiting PAK4 activity and subsequently reducing tumor growth and metastasis [57,58,59]. This evidence concerns the gene PAK4 and neoplasm.